



Cite this: *Org. Biomol. Chem.*, 2017, 15, 619

Construction of a polyproline structure with hydrophobic exterior using octahydroindole-2-carboxylic acid†

Vladimir Kubyshkin* and Nediljko Budisa*

The proline analogue (2*S*,3*aS*,7*aS*)-octahydroindole-2-carboxylic acid (Oic) has been previously applied as a proline substitute in pharmacologically active peptides and as a structural component of the antihypertensive drug Perindopril. Herein, we describe the formation of an oligoproline structure by an Oic oligomer. A series of Oic oligomers were investigated to show the structural and energetic contribution of appended residues to the structure. NMR investigation of these oligomers revealed an all-*trans* amide bond structure, and we provide evidence that a cascade-like mechanism is responsible for the all-*trans* folding cooperativity. X-ray crystallography of the Oic-hexapeptide clearly demonstrates that the all-*trans* structure of the Oic oligomer is a polyproline II helix. Thus, as a hydrophobic proline analog with a highly stable *trans*-amide bond, Oic represents an ideal building block for hydrophobic sites of polyproline II structures in biologically relevant contexts.

Received 21st October 2016,
Accepted 7th December 2016

DOI: 10.1039/c6ob02306a

www.rsc.org/obc

Introduction

Polyproline-II (P_{II}) is a ubiquitous secondary structural class in peptides and proteins that occupies a unique region on the Ramachandran plot.¹ The name P_{II} was originally coined to describe the structure that emerged upon mutarotation of polyproline dissolved in water.^{2,3} Later discoveries showed the abundance of P_{II} structures in a diversity of sequence folds. It was further shown that P_{II} helices can consist of various poly-amino acid sequences and do not necessarily contain proline.⁴ As an extended structure, P_{II} is common in unfolded proteins,⁵ and even single *N*-acylated amino acids exhibit spectroscopic signatures of this conformation.⁶

Since P_{II} structures do not necessarily contain proline in the linear sequences, some have proposed that P_{II} be renamed 'polypeptide-II'.⁷ However, as the most conformationally restricted among the canonical amino acids, proline (Fig. 1; **1**) is uniquely effective at sustaining the P_{II} structure backbone.^{8,9} Accordingly, proline-rich sequences can serve as scaffolds for functionalized P_{II} motifs.¹⁰ For example, proline-rich antimicrobial¹¹ and cell-penetrating peptides¹² are known to adopt




Fig. 1 Structures of proline (**1**, Pro), (2*S*,3*aS*,7*aS*)-octahydroindole-2-carboxylic acid (**2**, Oic) and Perindopril (**3**).

the P_{II} fold with the help of amphipathic interactions in a membrane environment. Exploring this concept, Filon *et al.* constructed an amphipathic, cell-penetrating P_{II} peptide by functionalizing the hydroxyl groups on an oligo-hydroxyproline scaffold with polar and hydrophobic side-chains at defined helical sites.¹³ In another example, Pujals *et al.* increased cellular uptake of the cell-penetrating peptide SAP by replacing proline with silaproline at the hydrophobic P_{II} site.^{14,15} Notably, a simple P_{II} structure (3.0 residues per turn) can serve as an effective molecular ruler in spectroscopic studies (*e.g.*, FRET).¹⁶

The kinetic and thermodynamic stability of the peptidyl-prolyl *trans*-peptide bond has a direct impact on the stability of proline-rich P_{II} structures.¹⁷ Experiments with proline

Biocatalysis group, Institute of Chemistry, Technical University of Berlin, Müller-Breslau-Str., 10, 10623 Berlin, Germany. E-mail: kubyshkin@win.tu-berlin.de, nediljko.budisa@tu-berlin.de

† Electronic supplementary information (ESI) available: Extended experimental details and analytical data; copies of the NMR spectra. CCDC 1510246 and 1510247. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6ob02306a






Fig. 2 *trans*–*cis* amide equilibrium of proline residue (above), *exo*-pucker of the proline side chain (below).

analogues showed that anchoring the proline ring in the *exo*-pucker conformation increases the preference for the *trans*-amide bond, which has enabled the construction of more stable P_{II} structures.^{18,19} This effect has been attributed to the $n \rightarrow \pi^*$ donative interaction between the carbonyl groups in the sequence (Fig. 2).^{20,21} Recently, we suggested that the donative effect may be enhanced through a cascade effect in the chain of the peptide bonds, leading to cooperative formation of the all-*trans* structural fold.²²

(2*S*,3*aS*,7*aS*)-Octahydroindole-2-carboxylic acid (2, commonly referred as Oic) is a proline analogue that has been used as a building block for the construction of pharmacologically relevant sequences, particularly bradykinin antagonists.^{23,24} Solution NMR structures²⁵ have demonstrated that the Oic cyclohexane ring adopts a chair conformation in these peptides, which may anchor the proline in the *exo*-pucker conformation. A recent theoretical study of the methylamide of *N*-acetyl Oic suggested the ϵ backbone conformation for this residue is predominant in solution.²⁶

In addition, Oic is a structural constituent of the antihypertension drug Perindopril (3). Early NMR studies have demonstrated a remarkably high *trans*-amide ratio (>90%) for the peptidyl-Oic constituent of Perindopril at high and low pH values.²⁷ These results suggest Oic may be a good candidate for construction of a P_{II} structure. Here, we demonstrate that Oic is capable of forming a stable and regular polyproline structure in solution, supported by the presence of a P_{II} conformation in crystals of an Oic hexamer.




Fig. 3 Structures of the amino acids taken for comparison of their physicochemical properties: 1, 2, 4, 5.

Results and discussion

Physicochemical comparison of Oic with (4*S*)- and (5*S*)-methylproline

We first aimed to physicochemically characterize Oic (2) in common model frames. Proline (1), (4*S*)-methylproline (4), and (5*S*)-methylproline (5) were used for comparison (Fig. 3). Reports have suggested that 4 exhibits a larger *trans*-content than proline due to the *exo*-pucker anchoring.^{18,28} In contrast, 5 is expected to sustain a *trans*-amide content similar to that of proline, despite the lower barrier of rotation for the amide due to the $\delta^{(cis)}$ -substitution.^{29–31}

Our results indicate that Oic combines these structural impacts of $\gamma^{(cis)}$ - and $\delta^{(cis)}$ -substitutions. The *trans*-amide content in Ac-Oic-OMe was among the highest reported to date (Table 1) for a proline analogue (*e.g.*, higher than that in analogous (4*R*)-fluoro- and hydroxyproline models).²¹

The high *trans*-amide content may be a result of a stabilized *exo*-pucker due to the restricted chair conformation of the cyclohexane ring and a stronger $n \rightarrow \pi^*$ donation imposed by this conformational arrangement. Previously, we proposed ΔpK_a and ΔpK_a^* (eqn (1) and (2) for *N*-acetyl amino acids) as the descriptive parameters for this interaction.²² Here, we found that the ΔpK_a and ΔpK_a^* values are indeed larger for 4 and 5 than for proline, whereas Oic shows the largest values, indicating a strong $n \rightarrow \pi^*$ alignment.

$$\Delta pK_a = pK_a(\textit{trans}) - pK_a(\textit{cis}) \quad (1)$$

$$\Delta pK_a^* = \log_{10} \frac{K_{\textit{trans}/\textit{cis}}(\textit{acid})}{K_{\textit{trans}/\textit{cis}}(\textit{salt})} \quad (2)$$

The crystal structure of Ac-Oic-OMe (Fig. 4A) illustrates the *exo*-pucker anchoring by the chair cyclohexane conformation.³² Careful inspection of the structure reveals that the

Table 1 Thermodynamic properties of the amino acids 1, 2, 4 and 5 in model compounds as studied by ¹H NMR in aqueous solution at 298 K

AA	AA (ammonium)	pK _a		ΔpK _a	ΔpK _a [*]	K _{trans/cis}		
		Ac-AA-OH (carboxyl)				Ac-AA-X		
		<i>s-trans</i>	<i>s-cis</i>			X = O [−]	X = OH	X = OMe
1 (Pro)	10.68	3.55	2.85	0.70	0.67	0.81 ± 0.02	3.77 ± 0.05	4.95 ± 0.05
4	10.73	3.54	2.79	0.75	0.78	1.03 ± 0.01	6.24 ± 0.11	8.05 ± 0.13
5	10.54	3.83	3.03	0.80	0.76	0.65 ± 0.02	3.73 ± 0.06	4.64 ± 0.02
2 (Oic)	10.57	3.84	2.98	0.86	0.83	1.09 ± 0.01	7.30 ± 0.16	9.38 ± 0.40






Fig. 4 A. X-ray crystal structure of Ac-Oic-OMe (grey – carbon, blue – nitrogen, red – oxygen). B. Kinetics of the *cis*–*trans* isomerization of Ac-Oic-OMe in aqueous solution.

Table 2 Amide rotation in Ac-AA-OMe models as found from ¹H EXSY NMR studies in aqueous solution

In Ac-AA-OMe		$k_{310 \text{ K}}, \text{ s}^{-1}$		$E_a, \text{ kJ mol}^{-1}$	
AA	$K_{trans/cis}$ (at 298 K)	<i>c</i> – <i>t</i>	<i>t</i> – <i>c</i>	<i>c</i> – <i>t</i>	<i>t</i> – <i>c</i>
1 (Pro)	4.95 ± 0.05	0.033 ± 0.002	0.0070 ± 0.0005	84.8 ± 0.2	88.8 ± 0.2
4	8.05 ± 0.13	0.041 ± 0.011	0.004 ± 0.001	84.3 ± 0.7	90.3 ± 0.7
5	4.64 ± 0.02	0.238 ± 0.011	0.055 ± 0.002	79.7 ± 0.1	83.5 ± 0.1
2 (Oic)	9.38 ± 0.40	0.074 ± 0.013	0.008 ± 0.001	82.7 ± 0.5	88.5 ± 0.3
In Ac-AA-O ⁻		$k_{340 \text{ K}}, \text{ s}^{-1}$		$E_a, \text{ kJ mol}^{-1}$	
AA	$K_{trans/cis}$ (at 298 K)	<i>c</i> – <i>t</i>	<i>t</i> – <i>c</i>	<i>c</i> – <i>t</i>	<i>t</i> – <i>c</i>
1 (Pro)	0.81 ± 0.02	0.075 ± 0.003	0.093 ± 0.003	91.0 ± 0.4	90.4 ± 0.3
4	1.03 ± 0.01	0.071 ± 0.009	0.066 ± 0.004	91.1 ± 0.7	91.3 ± 0.5
5	0.65 ± 0.01	1.083 ± 0.072	0.645 ± 0.028	83.4 ± 0.5	84.9 ± 0.4
2 (Oic)	1.09 ± 0.01	0.163 ± 0.003	0.153 ± 0.013	88.8 ± 0.3	88.9 ± 0.6

methyl-group of the acetyl constituent restricts the possible flipping of the cyclohexane chair conformation, thus locking the pyrrolidine ring in the *exo*-pucker conformation. Furthermore, the close proximity of the acetyl oxygen to the carboxyl carbon stabilizes the $n \rightarrow \pi^*$ contact.

The *cis*–*trans* rotational barriers in the Ac-AA-OMe models (Table 2) indicate that 5 and Oic have reduced rotational barriers due to the repulsion between the acetyl group and the 5-substituent of the proline ring in the ground state.³³ However, this effect is more moderate for Oic, due to the compact size of the CH₂-unit relative to the CH₃-group. Regarding the *trans*–*cis* amide rotation, the reduction of the rotational barrier is countered by the stabilizing $n \rightarrow \pi^*$ interaction, which contributes to the stability of the *trans*-ground state in Ac-Oic-OMe. Further analysis of the rotational velocities in Ac-Oic-OMe indicate an enthalpy driven transition (Fig. 4B), as expected.³⁴ In the salt form, the rotational barriers are heightened due to the increased amide resonance, which

is strengthened by the electrostatic interactions of the charges ($\text{CO}_2^- \leftrightarrow {}^+\text{N}=\text{C}-\text{O}^-$ attraction).

Oic in a peptide context

Next, we characterized Oic in a simple peptide context. To achieve this, Ac-GlyGlyOicGlyGly-NH₂ and Ac-GlyGlyProGlyGly-NH₂ were prepared by conventional Fmoc-solid phase peptide synthesis starting with Rink Amide resin (see ESI† for details). These peptides were then evaluated for their amide rotation properties (Table 3).

Our results indicate that the Pro-to-Oic mutation increased the relative stability of the *trans*-amide by approximately -1.5 kJ mol^{-1} , in a similar fashion to the Ac-AA-OMe model comparison. However, the amide rotational barrier reduction with the Pro-to-Oic mutation was much stronger than that observed in Ac-AA-OMe models. This difference may be a result of the greater steric interference presented by the peptide chain. In addition, for the *trans*-amide fraction, the



Table 3 Properties of the peptidyl-Pro and peptidyl-Oic peptide bonds in Ac-GlyGlyAAGlyGly-NH₂ peptides. Studied by ¹H NMR in buffered deuterium oxide solution

	GGProGG	GGOicGG
$K_{trans/cis}$ (at 298 K)	6.70 ± 0.20	12.3 ± 1.0
$\Delta G_{trans/cis}$, kJ mol ⁻¹	-4.71 ± 0.07	-6.22 ± 0.21
E^\ddagger , kJ mol ⁻¹	81.4 ± 0.3	76.8 ± 0.1
(At 310 K)		
<i>c-t</i>	85.8 ± 0.5	82.1 ± 0.1
<i>t-c</i>		




Fig. 5 ¹H{¹⁵N} sofast-HMQC spectra³⁵ of AcGG-AA-GGNH₂ peptides: blue – AA = Pro, red – AA = Oic. Recorded in aqueous medium at 277 K.

¹H{¹⁵N} single bond correlation spectra (Fig. 5) illustrate the fundamental similarity of the peptide chain conformations in the Pro- and Oic-containing peptides.

Crystal structure of an Oic-hexapeptide

Recently, Wilhelm *et al.* reported a crystal structure of a proline hexapeptide *p*-BrBz-(Pro)₆-OH in a P_{II} conformation (*p*-BrBz = *para*-bromobenzoyl).³⁶ We prepared an analogous hexapeptide composed of Oic residues with C-terminal amidation: *p*-BrBz-(Oic)₆-NH₂. The crystal structure of this peptide clearly demonstrates an all-*trans* P_{II} fold with all pyrrolidine rings in the *exo*-pucker conformations and perfect 3 residues/1 turn periodicity.³² In contrast to the hexaproline structure

(which shows 9.0 Å per turn (ref. 36 and 37)), the hexa-Oic structure was more compact, measuring approximately 8.6–8.7 Å per one helical turn (Fig. 6A).

Regarding the N-terminal region, the *para*-bromobenzoyl moiety appeared tilted, with a N-C(=O)-C-CH (*ortho*) torsion angle of approximately 68° (*versus* the 51° angle in the oligo-proline structure). This tilting results from the strong spatial clash between the aromatic ring and the δ-CH pyrrolidine portion.³⁸ In solution, this spatial clash substantially reduces the rotational barrier for this amide fragment. Thus, ¹H NMR spectra of the peptide in methanol (at 298 K) demonstrate the presence of two rotameric forms ($K_{trans/cis} = 2.5$) with relatively high transition velocities: 1.96 ± 0.20 and 0.84 ± 0.05 s⁻¹ for *cis*-to-*trans* and *trans*-to-*cis* rotations, respectively. For other amides, the ¹H ROESY spectra indicate an all-*trans* structure, consistent with the crystal observations (Fig. 6B). Our molecular modelling suggests that the *cis*-*p*-BrBz fragment folds into the first turn of the P_{II} helix, while the *trans*-*p*-BrBz fragment is exposed in solution. The high content of the N-terminal *cis*-form thus results from the stabilizing hydrophobic contacts of *p*-BrBz with the first three residues Oic¹–Oic³. The rotameric state of this fold also strongly influences the ¹H chemical shifts of the first helical turn residues in the two rotameric species.

Oic oligopeptides

We next wished to study the events accompanying the growth of the polypeptide chain and the possibility of specific aggregation events. We prepared a series of oligopeptides with the structure Ac-(Oic)_N-OH, where N was varied from 1 to 6. The peptides were synthesised on an Fmoc-Oic-pre-loaded 2-chlorotrityl resin, and the full-length peptides were cleaved mildly with 25 vol% hexafluoroisopropanol in dichloromethane, as described.³⁹

The peptides were well soluble in methanol (as well as other polar organic solvents). Peptides with N = 2–6 were very poorly soluble in water. Conversion to salts (with phosphate buffer, pH 7) enhanced their aqueous solubility. The NMR studies with the salt Ac-(Oic)_N-O⁻ species were then conducted




Fig. 6 A. X-ray crystal structure of *p*-BrBz-(Oic)₆-NH₂ oligopeptide in P_{II} conformation. B. α- and δ-CH fragment of the ¹H cross-relaxation spectra of this peptide in deuteriomethanol at 298 K and 700 MHz frequency. Only the exchange due to N-terminal rotation of *para*-bromobenzoyl fragment is seen in NOESY. In ROESY positive cross-peaks between α-CH and δ-CH spectral regions indicate the all-*trans* conformation.



in deuterium oxide. The concentration was 20 g l^{-1} for the $\text{Ac}(\text{Oic})_N\text{O}^-$ with $N = 1\text{--}5$, while the sample concentration of $\text{Ac}(\text{Oic})_N\text{O}^-$ with $N = 6$ was approximately 10 g l^{-1} due to its poor solubility. The NMR studies were also performed in deuteromethanol for the acidic $\text{Ac}(\text{Oic})_N\text{OH}$ species at 20 g l^{-1} for all studied oligomers.

In deuteromethanol the ^1H NOESY spectra showed a *trans*-amide bond with characteristic $\alpha\text{-CH} \leftrightarrow \delta\text{-CH}$ nuclear Overhauser effect (NOE) for the internal positions and a $\text{CH}_3 \leftrightarrow \delta\text{-CH}$ NOE for the N-terminal positions. The *trans*-amide constituted 80% of the population for $N = 1$ and $\geq 90\%$ for $N = 2$, whereas in oligomers with $N \geq 3$ only the all-*trans* conformation was observed. In this conformation, all the $\alpha\text{-CH}$ resonances appear as doublets of doublets with one J between 10.0 and 10.5 Hz and another between 7.1 and 8.2 Hz. Thus, the peptide backbone conformations all exhibit exceptional regularity, with the *exo*-pucker conformation predominant in the side-chain.⁴⁰

The ^1H NMR spectra for samples in deuterium oxide also indicated the dominance of the all-*trans* fold; however, minor populations of other folds were also observed (*vide infra*).

^1H diffusion ordered spectra (DOSY) of the oligomeric peptides demonstrated a systematically decreasing diffusion, which correlated well with the increments in N . The diffusion coefficients obtained in DOSY were converted to molecular volumes using the Stokes–Einstein relationship according to eqn (3).⁴¹ These volumes were compared with theoretical COSMO volumes obtained in semi-empirical modelling (see eqn (4)). The resulting prediction correlated fairly well with the experimental values for both the methanol and deuterium oxide solutions (Fig. 7A).

$$\log V[\text{\AA}^3] = 3 \left(-\log D[\text{m}^2 \text{s}^{-1}] + \log \frac{T[\text{K}]}{\eta[\text{Pa s}^{-1}]} - 13.928 \right) \quad (3)$$

$$V[\text{\AA}^3] = 10.9 + 1.223 \cdot \text{MW} [\text{Da}] \quad (4)$$

In the ^1H NOESY spectra, the NOEs for samples in deuterium oxide appeared positive for the shorter oligomers and

negative for the longer oligomers. The sign inversion occurred between $N = 3$ and 4 at 700 MHz and between $N = 4$ and 5 at 500 MHz, when measured at 298 K.

Next, we converted the $\log D$ values obtained in DOSY into correlation times τ_c according to eqn (5) (all SI units)⁴¹ and plotted NOE *versus* $\tau_c \omega_0$, where ω_0 is the angular Larmour frequency. According to the theory, the sign inversion should occur at $\tau_c \omega_0 = 1.12$,⁴² which was indeed the experimental result (Fig. 7B). Thus, the molecular sizes derived by DOSY (spatial diffusion) were consistent with those derived by NOESY (rotational diffusion).

$$\tau_c = \frac{k^2 T^2}{126 \pi^2 \eta^2} 10^{-3 \log D} \quad (5)$$

Overall the diffusion data indicated the absence of specific aggregation, despite the low aqueous solubility ($\leq 10 \text{ g l}^{-1}$) of the peptide with $N = 6$. However, the diffusion coefficient error is higher for the soluble fraction in aqueous conditions at $N = 5$ and 6. In addition, the applicability of the Stokes–Einstein equation, which assumes rigid spheres, clearly indicates sufficient molecular rigidity of the oligopeptide chains.⁴³ We also found for the NOE (y -axis) that the errors in Fig. 7B are similar for both N-terminal ($\text{CH}_3 \leftrightarrow \delta\text{-CH}^1$) and internal ($\alpha\text{-CH}^{1-(N-1)} \leftrightarrow \delta\text{-CH}^{2-N}$) positions, only for higher oligomers. This might indicate an increase in structural rigidity for longer oligomers.

Cooperativity of oligopeptide folding

Perhaps the most interesting question addressed by the oligopeptide studies is the degree of acidity of the C-terminal group. We previously observed that the acidity of the $\text{Ac}(\text{Pro})_2\text{OH}$ peptide with the *trans*-Pro–Pro amide bond depends on the rotameric state of the upstream acetyl-fragment.²² Namely, the *trans*–*trans* peptide (pK_a 3.59) exhibited a drop in acidity of approximately 0.1 pK_a unit relative to the *cis*–*trans* isoform. This result suggests cooperativity of the all-*trans* fold, which we assign to a cascade of donative interactions established between the carbonyl groups in the peptide chain.




Fig. 7 A. Dependence of the molecular volume of $\text{Ac}(\text{Oic})_N\text{OH}$ on the number of residues N : black – semi-empirical calculations, red – experimental in deuteromethanol (acidic form), blue – experimental in deuterium oxide (salt form); measured by ^1H DOSY at 700 MHz frequency and 298 K. B. The correlation time problem in $\text{Ac}(\text{Oic})_N\text{O}^-$. Inversion of the NOE sign in deuterium oxide samples occurs between lower and higher oligomers; the theoretical zero-cross point is at $\tau_c \omega_0 = 1.12$. The correlation time values were obtained from experimental $\log D$ values measured in ^1H DOSY according to eqn (5). The data were collected at 700 and 500 MHz ^1H frequency at 298 K.






Fig. 8 Dependence of the C-terminal pK_a on the oligomeric number N in all-*trans* $\text{Ac}-(\text{Oic})_N\text{-OH}$. Measured in buffered aqueous solutions at 298 K by ^1H NMR.




Fig. 9 Manifestation of the cascade-effect in an all-*trans* polyproline peptide chain.

We also measured the C-terminal acidity of the all-*trans* peptides in the $\text{Ac}-(\text{Oic})_N\text{-OH}$ oligomers by analysing ^1H NMR chemical shifts obtained at different pH values. In this case, the acidity of $\text{Ac}-(\text{Oic})_N\text{-OH}$ ($N = 1$) with the *cis*-amide (pK_a 2.97) can serve as a reference. The pK_a increased by 0.8–0.9 units (see Table 1) in the *trans*-isoform of this compound, as the $n \rightarrow \pi^*$ donation was stabilized by the geometry of the Oic residue. For higher oligomers with $N \geq 2$, the pK_a is further elevated by approximately 0.2–0.3 units (*i.e.*, ~ 1.1 – 1.7 kJ mol^{-1}) due to the putative cascade effect (Fig. 8 and 9). The cascade effect should strengthen the alignment of the carbonyl groups throughout the peptide chain. The available data clearly indicate that the cascade effect is transmitted sufficiently over one residue and decays very quickly through the all-*trans* peptide chain. The cascade phenomenon might therefore represent a driving force for P_{11} nucleation in peptide segments.

Minor conformational forms in the oligopeptides

As noted previously, in methanol samples, only the all-*trans* conformation was observed in the ^1H NMR spectra of $\text{Ac}-(\text{Oic})_N\text{-OH}$ with $N \geq 3$. A more complex situation occurred for $\text{Ac}-(\text{Oic})_N\text{-O}^-$ peptides in phosphate buffer, since the C-terminal group is a carboxylate, in which the carbonyl exhibits minimal electrophilicity. Whereas at $N = 1$ the *cis*-amide content was 48%, at $N = 2$ the distribution of *trans-trans*, *cis-trans*, *cis-cis* and *trans-cis* rotamers was 79:11:7:2, indicating a complex interdependence of the rotameric populations of two amides. For higher oligomers with $N = 3$ – 6 , the all-*trans* conformation is dominant. Nevertheless, some minor

fractions were persistently observed. We next aimed to identify the source of the minor conformational forms and their populations, which should provide a proper characterization of the relative stability of the peptide conformations.

In the aqueous samples of $\text{Ac}-(\text{Oic})_N\text{-O}^-$, the most prominent minor resonance was $\delta\text{-CH}$ at 3.98 ppm (see Fig. 10). In order to assign this form, we evaluated ^1H EXSY spectra at 330 K. In the EXSY spectra, this minor $\delta\text{-CH}$ signal exhibited an exchange with the N-terminal $\delta\text{-CH}$ but not the internal $\delta\text{-CH}$ resonances. In addition, one $\alpha\text{-CH}(\text{major}) \leftrightarrow \alpha\text{-CH}(\text{minor})$ and one $\text{CH}_3(\text{major}) \leftrightarrow \text{CH}_3(\text{minor})$ exchange together with an $\alpha\text{-CH}(\text{minor}) \leftrightarrow \text{CH}_3(\text{minor})$ NOE indicated that the minor form was a result of the N-terminal rotation. However, the intensity of this $\delta\text{-CH}$ (~ 17 – 18% for $N = 3$ – 6) minor signal was higher than for the other minor resonances ($\alpha\text{-CH}$ and CH_3 , ~ 6 – 10%), and it was remarkably higher than that of the $\text{Ac}-(\text{Oic})\text{-OME}$ model (10%).

Furthermore, we compared the ^1H NMR spectra of the methyl ester ($\text{Ac}-(\text{Oic})_6\text{-OME}$) and salt ($\text{Ac}-(\text{Oic})_6\text{-O}^-$) forms in methanol. The intensity of the (*cis*-Ac) $\delta\text{-CH}$ resonance increased when changing from the salt to methyl ester. This change was accompanied by the appearance of one additional CH_3 -resonance in ^1H and $^1\text{H}\{^{13}\text{C}\}$ HSQC spectra. The dependence of the N-terminal rotation state on the C-terminal charge can be explained by a cooperative formation of the all-*cis* (polyproline I) structure, which is favoured in the case of charged peptide termini.⁴⁴ The estimation of the *s-cis*-acetyl fragment originating from (a) the N-terminal rotation in the all-*trans* structure and (b) the formation of an all-*cis* conformation was performed by analysing three resolved CH_3 -resonances in $^1\text{H}\{^{13}\text{C}\}$ HSQC. These were: for $\text{Ac}-(\text{Oic})_6\text{-OME}$ 5 (a) and 1 (b) %, and for $\text{Ac}-(\text{Oic})_6\text{-O}^-$ 5 (a) and 3 (b) %, respectively (in the methanol solutions).

In deuterium oxide, the presumed all-*cis* fraction constituted about 2–3% for $\text{Ac}-(\text{Oic})_6\text{-O}^-$ and was not detected for $\text{Ac}-(\text{Oic})_6\text{-OME}$. In these aqueous conditions, the *cis*-Ac content due to the N-terminal rotation in the all-*trans* form was 10–12%, and the *trans*-to-*cis* rotation rate was about 0.02 s^{-1} (for $\text{Ac}-(\text{Oic})_N\text{-O}^-$ with $N = 3$ – 6 ; at 330 K).

Therefore, similar to the *p*-BrBz-(Oic)₆-NH₂ peptide, the N-terminal rotation occurs in $\text{Ac}-(\text{Oic})_N\text{-OH/O}^-$ peptides. In addition, the all-*cis* fraction might be formed at a very low, yet detectable, level. The low percentage of the minor conformation explains why this fraction is obscured by the main resonances and is only visible when combined with other signals. Overall, the low percentage found for the minor conformational states indicates the high relative stability of the major cooperative all-*trans* fold for the oligo-Oic chain.

Conclusions

In summary, we have demonstrated that peptidyl-Oic is capable of creating a strong *trans*-amide carbonyl alignment in peptide structures. This rotameric state is stabilized by the anchoring of the pyrrolidine pucker in the *exo*-conformation






Fig. 10 α -CH, δ -CH region of the ^1H NMR spectra of $\text{Ac}-(\text{Oic})_6\text{-O}^-$ (left) and $\text{Ac}-(\text{Oic})_6\text{-OMe}$ (right) in deuteromethanol (bottom) and deuterium oxide (top). Measurements were performed at 298 K in stimulated echo pulse sequence used for solvent suppression. Residual OH resonance of deuteromethanol is marked with an asterisk. The resonances exchanged in ^1H EXSY experiments (at 330 K) are marked with double-headed lines below the spectra.

by the cyclohexane ring. The all-*trans* backbone state in oligomeric structures is stabilized by the high *trans*-amide propensity of a single Oic-residue as well as the cascade effect established in the peptide chain. Furthermore, the residual rotational freedom of the N-terminal fragment (acetyl or *para*-bromobenzoyl) is the major source of alternative conformational states. The cascade effect is the enhancement of the original carbonyl alignment energy by a preceding residue. For Oic, the alignment energy is enhanced by approximately 1/3–1/4 (compared to an enhancement by 1/6 for a proline oligopeptide, as determined previously²²). As a P_{II} stabilizing residue, Oic represents an ideal candidate for construction of hydrophobic sites in a plethora of biologically relevant P_{II} structures. We also envision that all-Oic structures might serve as a starting point for construction of a transmembrane P_{II} helix, a motif non-existent in nature.

Experimental section

(2*S*,3*aS*,7*aS*)-Octahydroindole-2-carboxylic acid (Oic) was obtained from commercial sources, (4*S*)-methylproline was synthesized as previously described,⁴⁵ and (5*S*)-methylproline was synthesized according to Mohite *et al.*⁴⁶

1-Acetyl-(2*S*,3*aS*,7*aS*)-octahydroindole-2-carboxylic acid

Oic (156 mg; 0.92 mmol; 1 equiv.) was mixed with acetic anhydride (200 μl ; 2.1 mmol; 2.3 equiv.) in dichloromethane

(2 ml). After 30 min, the solvent was removed under reduced pressure. The residue was taken up in water and freeze dried to give 192 mg Ac-Oic as a white powder (98% yield). ^1H NMR (700 MHz, D_2O , phosphate buffer), δ : 4.23 (dd, $J = 9.5$ and 7.9 Hz, *s-cis*) and 4.12 (dd, $J = 10.1$ and 8.7 Hz, *s-trans*) (1H, α -CH), 3.97 (m, *s-cis*) and 3.82 (m, *s-trans*) (1H, δ -CH), 2.28 (m, *s-trans*) and 2.19 (m, *s-cis*) (1H, γ -CH), 2.22 and 2.00 (two m, *s-cis*) and 2.11 and 1.89 (two m, *s-trans*) (2H, β -CH₂), 2.03 (s, *s-trans*) and 1.83 (s, *s-cis*) (3H, CH₃), 1.85 and 1.40 (two m, *s-trans*) and 1.82 and 1.26 (two m, *s-cis*) (2H, CH₂), 1.66 and 1.57 (two m, CH₂), 1.60 and 1.09 (two m, CH₂), 1.39 and 1.23 (two m, CH₂). $^{13}\text{C}\{^1\text{H}\}$ (126 MHz, D_2O , phosphate buffer), δ : 179.9 (CO₂⁻), 172.7 (*s-cis*, NCO) and 171.7 (*s-trans*, NCO), 63.3 (*s-cis*, α -CH) and 61.5 (*s-trans*, α -CH), 59.9 (*s-trans*, δ -CH) and 58.2 (*s-cis*, δ -CH), 36.6 (*s-trans*, γ -CH) and 35.5 (*s-cis*, γ -CH), 32.7 (*s-cis*, β -CH₂) and 31.1 (*s-trans*, β -CH₂), 27.0 (*s-trans*, CH₂) and 26.0 (*s-cis*, CH₂), 25.1 and 24.9 (CH₂), 23.34 and 23.32 (CH₂), 20.81 (*s-trans*, CH₃) and 20.77 (*s-cis*, CH₃), 19.8 and 19.6 (CH₂). Mass-spectrum (ESI), Th: 212.13 [$\text{M} + \text{H}$]⁺, 234.11 [$\text{M} + \text{Na}$]⁺. [α]_D = -60 ($c = 1.0$, methanol, 298 K).

Methyl 1-acetyl-(2*S*,3*aS*,7*aS*)-octahydroindole-2-carboxylate

Ac-Oic (74 mg; 0.35 mmol) was dissolved in methanol (2 ml) and trimethylsilane (0.075 ml) was subsequently added. The mixture was stirred overnight, methanol was removed under reduced pressure and the residue was purified by silica gel column using a methanol–ethyl acetate mixture (1:19) as an eluent ($R_f = 0.5$). 79 mg of Ac-Oic-OMe was obtained as a



colourless oil, which later crystallized (quantitative yield). ^1H NMR (700 MHz, D_2O), δ , only *s-trans*: 4.34 (dd, $J = 10.0$ and 8.5 Hz, 1H, $\alpha\text{-CH}$), 3.89 (m, 1H, $\delta\text{-CH}$), 3.69 (s, 3H, CH_3O), 2.38 (m, 1H, $\gamma\text{-CH}$), 2.15 and 2.01 (two m, 2H, $\beta\text{-CH}_2$), 2.06 (s, 3H, $\text{CH}_3\text{C=O}$), 1.91 and 1.37 (two m, 2H, CH_2), 1.68 and 1.61 (two m, 2H, CH_2), 1.63 and 1.14 (two m, 2H, CH_2), 1.41 and 1.23 (two m, 2H, CH_2). $^{13}\text{C}\{^1\text{H}\}$ (126 MHz, D_2O), δ , only *s-trans*: 175.1 (CO_2Me), 172.3 (NCO), 59.5 ($\delta\text{-CH}$), 59.0 ($\alpha\text{-CH}$), 36.9 ($\gamma\text{-CH}$), 30.3 ($\beta\text{-CH}_2$), 27.0 (CH_2), 24.9 (CH_2), 23.2 (CH_2), 20.5 (CH_3), 19.5 (CH_2). Mass-spectrum (ESI), Th: 226.14 [$\text{M} + \text{H}$] $^+$. $[\alpha]_{\text{D}} = -72$ ($c = 1.0$, methanol, 298 K).

N-Acetyl derivatives and their methyl esters for (4*S*)- and (5*S*)-methylprolines were prepared in analogous procedures.

1-Fluorenylmethoxycarbonyl-(2*S*,3*aS*,7*aS*)-octahydroindole-2-carboxylic acid

Oic (0.75 g; 4.43 mmol; 1 equiv.) was dissolved in a 10% sodium carbonate solution (5 ml). Some water and acetone was added, and the solution was cooled down by an ice bath. A solution of Fmoc chloride (1.26 g; 4.87 mmol; 1.1 equiv.) in acetone (5 ml) was added dropwise upon stirring over 40 min. The mixture was stirred overnight at ambient temperature. The mixture was then diluted by water to reach a volume of 250 ml. It was then washed by diethyl ether (2 \times 75 ml), acidified by addition of solid potassium hydrogen sulphate (to pH ≤ 2) and extracted by ethyl acetate (4 \times 50 ml). Ethyl acetate fractions were dried over sodium sulphate and filtered, and the solvent was removed under reduced pressure. The residue was mixed with an acetonitrile–water mixture and freeze-dried. 1.72 g of Fmoc-Oic was obtained as a white powder (99% yield). ^1H NMR (700 MHz, CD_3OD), δ : 7.81 (m, 2H), 7.67–7.61 (m, 2H), 7.40 (m, 2H), 7.33 (m, 2H), 4.52 and 4.48 (two dd, $J = 10.7$, 5.7 Hz) and 4.34 and 4.26 (two m) (2H, $\text{CH}_2\text{-O}$), 4.34 and 4.16 (two m, 1H, $\alpha\text{-CH}$), 4.25 and 4.16 (two m, 1H, CH), 3.89 and 3.42 (two m, 1H, $\delta\text{-CH}$), 2.36 and 2.20 (two m, 1H, $\gamma\text{-CH}$), 2.28 and 2.09, 2.24 and 1.94 (four m, 2H, $\beta\text{-CH}_2$), 2.07, 1.80–1.68, 1.64–1.19 and 1.01 (series of multiplets, 6H, 3 \times CH_2). $^{13}\text{C}\{^1\text{H}\}$ NMR (126 MHz, CD_3OD), δ : 175.0 and 174.6 (CO_2H), 155.0 and 154.8 (NCO), 144.12, 144.08, 144.0, 143.7, 141.5, 141.4, 141.2 and 141.1 (all C), 127.43, 127.37, 127.33, 126.81, 126.75, 124.92, 124.85, 124.5, 119.54 and 119.49 (all CH), 67.6 and 66.8 ($\text{CH}_2\text{-O}$), 58.9 and 58.8 ($\alpha\text{-CH}$), 58.1 and 57.7 (CH), 47.2 and 47.1 ($\delta\text{-CH}$), 36.7 and 36.3 ($\gamma\text{-CH}$), 32.4 and 31.3 ($\beta\text{-CH}_2$), 30.4, 27.3, 27.0, 25.3, 23.4, 23.3, 20.1 and 20.1 (all CH_2). Mass-spectrum (ESI), Th: 392.18 [$\text{M} + \text{H}$] $^+$. $[\alpha]_{\text{D}} = -28$ ($c = 1.0$, methanol, 298 K).

Acknowledgements

The authors would like to thank Paula Nixdorf and Dr Elisabeth Irran (TU Berlin) for performing crystallographic studies. DFG research group FOR 1805 is acknowledged for a postdoctoral fellowship (VK). Dr Marcie Jaffee (Atlanta, USA) is gratefully acknowledged for a revision of the manuscript.

References

- S. A. Hollingsworth and P. A. Karplus, *Biomol. Concepts*, 2010, **1**, 271–283.
- J. Kurtz, A. Berger and E. Katchalski, *Nature*, 1956, **178**, 1066–1067.
- F. Conti, M. Piatelli and P. Viglino, *Biopolymers*, 1969, **7**, 411–415.
- A. A. Adzhubei, M. J. E. Sternberg and A. A. Makarov, *J. Mol. Biol.*, 2013, **425**, 2100–2132.
- J. Makowska, S. Rodziewicz-Motowidło, K. Bagińska, J. A. Vila, A. Liwo, L. Chmurzyński and H. A. Sheraga, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 1744–1749.
- I. Gokce, R. W. Woody, G. Anderluh and J. H. Lakey, *J. Am. Chem. Soc.*, 2005, **127**, 9700–9701.
- S. A. Hollingsworth, D. S. Berkholz and P. A. Karplus, *Protein Sci.*, 2009, **18**, 1321–1325.
- Z. Shi, K. Chen, Z. Liu, A. Ng, W. C. Bracken and N. R. Kallenbach, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 17964–17968.
- A. M. Brown and N. J. Zondlo, *Biochemistry*, 2012, **51**, 5041–5051.
- M. P. Williamson, *Biochem. J.*, 1994, **297**, 249–260.
- M. Scocchi, A. Tossi and R. Gennaro, *Cell. Mol. Life Sci.*, 2011, **68**, 2317–2330.
- S. Pujals and E. Giralt, *Adv. Drug Delivery Rev.*, 2008, **60**, 473–484.
- Y. A. Filon, J. P. Anderson and J. Chmielewski, *J. Am. Chem. Soc.*, 2005, **127**, 11798–11803.
- S. Pujals, J. Fernández-Carneado, M. J. Kogan, J. Martinez, F. Cavelier and E. Giralt, *J. Am. Chem. Soc.*, 2006, **128**, 8479–8483.
- It was later demonstrated that oligo-silaproline is also able to form an all-*trans* structure, see: C. Martin, B. Legrand, A. Lebrun, D. Berthomieu, J. Martinez and F. Cavelier, *Chem. – Eur. J.*, 2014, **20**, 14240–14244.
- (a) B. Schuler, E. A. Lipman, P. J. Steinbach, M. Kumke and W. A. Eaton, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 2754–2759; (b) H. Sahoo, D. Roccatano, A. Hennig and W. M. Nau, *J. Am. Chem. Soc.*, 2007, **129**, 9762–9772; (c) E. Dolgih, W. Ortiz, S. Kim, B. P. Krueger, J. L. Krause and A. E. Roitberg, *J. Phys. Chem. A*, 2009, **113**, 4639–4646.
- W. J. Wedemeyer, E. Welker and H. A. Scheraga, *Biochemistry*, 2002, **41**, 14637–14644.
- M. D. Shoulders, J. A. Hodges and R. T. Raines, *J. Am. Chem. Soc.*, 2006, **128**, 8112–8113.
- M. Kümin, L.-S. Sonntag and H. Wennemers, *J. Am. Chem. Soc.*, 2007, **129**, 466–467.
- M. P. Hinderaker and R. T. Raines, *Protein Sci.*, 2003, **12**, 1188–1194.
- M. D. Shoulders and R. T. Raines, *Annu. Rev. Biochem.*, 2009, **78**, 929–958.
- V. Kubyskhin, P. Durkin and N. Budisa, *New J. Chem.*, 2016, **40**, 5209–5220.
- J. M. Stewart, *Peptides*, 2004, **25**, 527–532.



- 24 S. Deekonda, D. Rankin, P. Davis, J. Lai, F. Porreca and V. J. Hruby, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 4148–4152.
- 25 (a) D. J. Kyle, P. R. Blake, D. Smithwick, L. M. Green, J. A. Martin, J. A. Sinsko and M. F. Summers, *J. Med. Chem.*, 1993, **36**, 1450–1460; (b) W. Guba, R. Haessner, G. Breipohl, S. Henke, J. Knolle, V. Santagada and H. Kessler, *J. Am. Chem. Soc.*, 1994, **116**, 7532–7540; (c) J. Sejbal, J. R. Cann, J. M. Stewart, L. Gera and G. Kotovych, *J. Med. Chem.*, 1996, **39**, 1281–1292; (d) J. Sejbal, Y. Wang, J. R. Cann, J. M. Stewart, L. Gera and G. Kotovych, *Biopolymers*, 1997, **42**, 521–535.
- 26 J. Torras, J. G. Warren, G. Revilla-López, A. I. Jiménez, C. Catiuela and C. Alemán, *Biopolymers*, 2014, **102**, 176–190.
- 27 J. P. Bouchet, J. P. Volland, M. Laubie, M. Vincent, B. Marchand and N. Platzner, *Magn. Reson. Chem.*, 1992, **30**, 1186–1195.
- 28 C. Siebler, R. S. Erdmann and H. Wennemers, *Angew. Chem., Int. Ed.*, 2014, **53**, 10340–10344.
- 29 N. G. Delaney and V. Madison, *Int. J. Pept. Protein Res.*, 1982, **19**, 543–548.
- 30 Y. K. Kang, *J. Mol. Struct. (THEOCHEM)*, 2002, **585**, 209–221.
- 31 K. Zhang, R. B. Teklerbhan, G. Schreckenbach, S. Wetmore and F. Schweizer, *J. Org. Chem.*, 2009, **74**, 3735–3743.
- 32 The crystal structures are deposited in Cambridge Crystallographic Data Centre under deposition numbers: Ac-Oic-OMe CCDC 1510246, *p*-BrBz-(Oic)₆-NH₂ CCDC 1510247.
- 33 E. Beausoleil, R. Sharma, S. W. Michnick and W. D. Lubell, *J. Org. Chem.*, 1998, **63**, 6572–6578.
- 34 C. Renner, S. Alefelder, J. H. Bae, N. Budisa, R. Huber and L. Moroder, *Angew. Chem., Int. Ed.*, 2001, **40**, 923–925.
- 35 P. Schanda, Ě. Kupče and B. Brutscher, *J. Biomol. NMR*, 2005, **33**, 199–211.
- 36 P. Wilhelm, B. Lewandowski, N. Trapp and H. Wennemers, *J. Am. Chem. Soc.*, 2014, **136**, 15829–15832.
- 37 Similarly, a 9.1 Å periodicity was recently described for the crystal structure of *cis*-4,5-methanoproline tetramer, see: G. Berger, M. Vilchis-Reyes and S. Hanessian, *Angew. Chem., Int. Ed.*, 2015, **54**, 13268–13272.
- 38 V. Kubyshkin, Y. Kheylik and P. K. Mykhailiuk, *J. Fluorine Chem.*, 2015, **175**, 73–83.
- 39 R. Bollhagen, M. Schmiedberger, K. Barlos and E. Grell, *J. Chem. Soc., Chem. Commun.*, 1994, 2559–2560.
- 40 M. Cai, Y. Huang, J. Liu and R. Krishnamoorthi, *J. Biomol. NMR*, 1995, **6**, 123–128.
- 41 Legend for eqn (3)–(5): *D* – diffusion coefficient in m² s⁻¹, *T* – absolute temperature in K, *η* – dynamic viscosity in Pa s⁻¹, *V* – molecular volume in Å³, MW – molecular weight in Da, *k* – Boltzmann constant in m² kg s⁻² K⁻¹, *τ_c* – correlation time in s rad⁻¹, *ω₀* – angular frequency in rad s⁻¹.
- 42 B. Luy, A. Frank and H. Kessler, Conformational Analysis of Drugs by Nuclear Magnetic Resonance Spectroscopy, in *Molecular Drug Properties - Measurement and Prediction*, ed. R. Mannhold, Wiley, 2008, pp. 207–254.
- 43 R. Evans, Z. Deng, A. K. Rogerson, A. S. McLachlan, J. J. Richards, M. Nilsson and G. A. Morris, *Angew. Chem., Int. Ed.*, 2013, **52**, 3199–3202.
- 44 M. Kuemin, S. Schweizer, C. Ochsenfeld and H. Wennemers, *J. Am. Chem. Soc.*, 2009, **131**, 15474–15482.
- 45 D. Dietz, V. Kubyshkin and N. Budisa, *ChemBioChem*, 2015, **16**, 403–406.
- 46 A. R. Mohite and R. G. Bhat, *J. Org. Chem.*, 2012, **77**, 5423–5428.

